VanEck Pharmaceutical ETF (PPH)
| Assets | $383.65M |
| Expense Ratio | 0.36% |
| PE Ratio | 19.02 |
| Shares Out | n/a |
| Dividend (ttm) | $1.63 |
| Dividend Yield | 2.07% |
| Ex-Dividend Date | Oct 2, 2023 |
| Payout Ratio | 39.46% |
| 1-Year Return | +1.08% |
| Volume | 49,166 |
| Open | 78.35 |
| Previous Close | 78.51 |
| Day's Range | 78.35 - 78.87 |
| 52-Week Low | 73.40 |
| 52-Week High | 83.35 |
| Beta | n/a |
| Holdings | 26 |
| Inception Date | Feb 1, 2000 |
About PPH
Fund Home PageThe VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is issued by VanEck.
Top 10 Holdings
56.80% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 8.43% |
| Novo Nordisk A/S | NVO | 6.61% |
| Johnson & Johnson | JNJ | 6.14% |
| Cencora | COR | 5.36% |
| McKesson Corporation | MCK | 5.27% |
| Novartis AG ADR | NVSN.MX | 5.12% |
| Haleon plc | HLN | 5.02% |
| AbbVie Inc. | ABBV | 5.00% |
| AstraZeneca PLC | AZN | 4.93% |
| Merck & Co., Inc. | MRK | 4.92% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Oct 2, 2023 | $0.3398 | Oct 6, 2023 |
| Jul 3, 2023 | $0.3891 | Jul 7, 2023 |
| Apr 3, 2023 | $0.6641 | Apr 10, 2023 |
| Dec 28, 2022 | $0.240 | Dec 30, 2022 |
| Oct 3, 2022 | $0.2696 | Oct 7, 2022 |
| Jul 1, 2022 | $0.2496 | Jul 8, 2022 |
News
Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.
Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.
Biotech Stocks Are Rallying, but the Outlook Isn't Good
The XBI has been climbing this month. On Tuesday it jumped 5.4% to close at $70.91.
Disruptive Tech Theme of the Week: Weight Loss Revolution
According to the latest CDC National Diabetes Statistics Report, more than 37 million people have diabetes in the U.S., or 11.3% of the population. The statistics for obesity are also dismal, as the W...
Weight Loss Drugs Could Prove Potent for PPH
Ozempic commercials are, at this point, ubiquitous and while that's an anecdotal example, it also represents confirmation that obesity drugs are the next big thing in the pharmaceuticals industry.
How the Pharmaceutical Industry Is Using AI
Industry-leading pharmaceutical firms are adopting artificial intelligence (AI) to drive value for the future of their enterprise. AI is currently being implemented within the industry to reduce human...
Growth, Innovation Could Fuel Pharma ETF Rebound
For much of 2020 and 2021, the pharmaceutical stock investment thesis revolved around development and disbursement of coronavirus vaccines. While that made for an obvious catalyst, and a rewarding one...
3 ETFs for the Healthcare Sector's Highs
Investors looking for equities suddenly have more than a few options to consider in this mini-market rally. Whether markets have really priced in Fed action or a possible recession already or not, inv...
This ETF Is Home to Some of the Top Healthcare Stocks
The healthcare sector isn't setting the investment world ablaze this year, but it is outperforming the broader market, underscoring its defense posture.
Pharma Stocks, ETFs Can Deal With Drug Pricing Legislation
This is a mid-term election year, meaning that some familiar issues investors should be aware of are popping up yet again. That includes reducing pharmaceutical prices.
Pharmaceuticals Stocks, ETFs Could Have Power Beyond 2022
Pharmaceuticals stocks and the related exchange traded funds are benefiting from the now-steady revenue stream provided by coronavirus vaccines, but with that priced into many pharmaceuticals equities...
Pharma Could Be Place to Be for Healthcare Winners, Value
Broadly speaking, the healthcare sector delivered some decent though not spectacular performances last year, with diversified exchange traded funds addressing the sector hindered by rough showings by ...
Pharma Could Be Fabulous in 2022
Pharmaceuticals stocks and the related exchange traded funds are turning solid performances in 2021. Investors looking for quality and growth traits might want to continue leaning on this corner of th...
Write a Prescription for Pharma Dividends With PPH
Domestic dividend growth is on a torrid pace this year, and market observers expect that the trend will continue in 2022. Investors searching for sector and industry exchange traded funds with which t...
Omicron Variant Could Be Potent for Pharma Stocks, ETFs
According to reports out Wednesday, the first U.S case of the Omicron variant of the coronavirus was discovered in California. More research is needed on the Omicron strain, but there's already ample ...
There's Power Lurking in This Pharma ETF
Blue-chip pharmaceuticals stocks are turning solid showings this year, but the group is lagging the broader market, indicating that some of the coronavirus vaccine blush is wearing off the group. Howe...
PPH Pertinent as Some Cheap Pharma Stocks Offer Big Dividend Growth
Healthcare stocks are solid but not spectacular performers. For example, the S&P 500 Health Care Index is higher by more than 17%, though that lags the broader market.
Strong Vaccine Demand Lifting Pharma Sales
There are multiple coronavirus vaccines on the market, and with the likelihood of booster shots increasing by the day, the revenue outlook for healthcare exchange traded funds, including the VanEck Ve...
Alzheimer's Drug Cost Pushes Pharmaceutical Prices Back Into the Spotlight
Biogen's (NASDAQ: BIIB) Aduhelm sparked a rally in the biotech giant's share price and hope that progress is being made in treating Alzheimer's. However, the news isn't free of controversy, and carrie...
Artificial Intelligence Set to Transform the Pharmaceutical Industry
The pharmaceuticals industry got a boost last year when a Covid-19 vaccine was introduced, but artificial intelligence (AI) could keep the sector and ETFs like the VanEck Vectors Pharmaceutical ETF (P...
Pharma Goes Beyond the Vaccine. ‘PPH' on the Verge of More Advances
Coming off a vaccine rally that started in the middle of 2020, the pharmaceutical industry will continue to evolve as technological advances make their way into the sector, which should help ETFs like...
Beyond the Vaccine: The Long Runway for Health and Pharmaceutical ETFs
With 2020 election season in the rearview mirror, it could be a great time to revisit health and pharmaceutical ETFs, including the VanEck Vectors Pharmaceutical ETF (NASDAQ: PPH). PPH tracks the MVIS...
Write A Prescription For This Pharma ETF
After scuffling amid political uncertainty leading up to Election Day, pharmaceutical stocks and exchange-traded funds are finally perking amid a spate of encouraging news regarding coronavirus vaccin...
Pharma Sector Steps up as a Portfolio Prescription
By VanEck Hope Springs Eternal Hopes of a return to normality are increasing after a year of pandemic-induced tumult. News that COVID-19 vaccines developed by Pfizer and BioNTech, and Moderna were mor...
Some Good Deals Are Available in Pharmaceuticals ETFs
Investors looking for compelling valuations don’t have to go deep into the lagging value factor. They can harness some growth with pharmaceuticals ETFs, including the VanEck Vectors Pharmaceutical ETF...
A Divergence Has Occurred In Healthcare
For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech.